A patient with hyperuricemia at an initial outpatient appointment with a rheumatologist: focus on adherence to urate-lowering therapy

DOI: https://doi.org/10.29296/25877305-2024-06-07
Issue: 
6
Year: 
2024

Professor L. Kozlova(1), MD; Professor V. Tsurko(2), MD; L. Grivko(3); Professor
G. Bagirova(1), MD; Associate Professor G. Kuchma(1), Candidate of Medical Sciences; U. Yakubova(1), Candidate of Medical Sciences
1-Orenburg State Medical University
2-I.M. Sechenov First Moscow State Medical University, Ministry of Health
of Russia (Sechenov University)
3-Nauka LLC, Orenburg

Hyperuricemia (HU) is a key risk factor for the development of gout and chronic kidney disease. The goal of HU therapy is to reduce the level of urate in the blood serum, helping to reduce exacerbations of gout, resolve tophi and prevent kidney damage. Purpose. To analyze the effectiveness of previous urate-lowering therapy (ULT) and treatment adherence in patients with HU. Material and methods. The study involved 38 patients with HU and articular syndrome. The survey included information about the frequency of patients' visits to a rheumatologist, their adherence to a hypouricemic diet, the regularity and duration of taking urate-lowering drugs, their dose, and the frequency of determining the level of uric acid (UA) in the blood. Results. 50% of patients complied with recommendations on non-pharmacological measures for HU. 32 patients had indications for ULT, of which 28.1% received this therapy. Of these, 8 patients took allopurinol (100–200 mg/day), 1 patient took febuxostat (80 mg/day). Determination of UA level in all cases was carried out no more than once a year. Dose adjustment of urate-lowering drugs based on UA levels was not performed in any case. During the last year, 13.2% of patients were examined by a rheumatologist. Conclusion. Adherence to ULT and monitoring of serum UA levels among patients with HU/gout remains low. Patients in most cases do not achieve target UA values, which leads to the development and more severe course of comorbid diseases and complications of gout.
Keywords: 
hyperuricemia
gout
adherence to therapy
urate-lowering therapy.

References: 
  1. Srivastava A., Kaze A.D., McMullan C.J. et al. Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD. Am J Kidney Dis. 2018; 71 (3): 362–70. DOI: 10.1053/j.ajkd.2017.08.017
  2. Zhou F., Yu G., Wang G. et al. Association of serum uric acid levels with the incident of kidney disease and rapid eGFR decline in Chinese individuals with eGFR >60 mL/min/1.73m2 and negative proteinuria. Clin Exp Nephrol. 2019; 23 (7): 871–9. DOI: 10.1007/s10157-019-01705-w
  3. Мазуров В.И., Башкинов Р.А., Гайдукова И.З. и др. Влияние бессимптомной гиперурикемии на коморбидные заболевания и возможности ее коррекции. РМЖ. 2021; 7: 24–30 [Mazurov V.I., Bashkinov R.A., Gaidukova I.Z. et al. The effect of asymptomatic hyperuricemia on comorbidities and the possibility of its correction. RMJ. 2021; 7: 24–30 (in Russ.)].
  4. Шальнова СА., Деев АД., Артамонова ГВ. и др. Гиперурикемия и ее корреляты в российской популяции (Результаты эпидемиологического исследования ЭССЕ-РФ). Рациональная фармакотерапия в кардиология. 2014; 10 (2): 153–9 [Shalnova S.A., Deev A.D., Artamonov G.V. et al. Hyperuricemia and its correlates in the russian population (results of ESSE-RF epidemiological study). Rational Pharmacotherapy in Cardiology. 2014; 10 (2): 153–9 (in Russ.)]. DOI: 10.20996/1819-6446- 2014-10-2-153-159
  5. Liu B., Wang T., Zhao H. et al. The prevalence of hyperuricemia in China: a meta-analysis. BMC Public Health. 2011; 11: 832. DOI: 10.1186/1471-2458-11-832
  6. Фомин В.В. Подагрическая (уратная) нефропатия. Consilium medicum. 2021; 23 (1): 11–4 [Fomin V.V. Gouty (urate) nephropathy. Consilium medicum. 2021; 23 (1): 11–4 (in Russ.)]. DOI: 10.26442/20751753.2021.1.200709
  7. Jaffe D.H., Klein A.D., Benis A. et al. Incident gout and chronic kidney disease: healthcare utilization and survival. BMC Rheumatol. 2019; 3 (11): 36–47. DOI: 10.1186/s41927-019-0060-0
  8. Драпкина О.М., Мазуров В.И., Мартынов А.И. и др. «В фокусе гиперурикемия». Резолюция Cовета экспертов. Кардиоваскулярная терапия и профилактика. 2023; 22 (4): 3564 [Drapkina OM., Mazurov VI., Martynov AI. et al. "Focus on hyperuricemia". The resolution of the Expert Council. Cardiovascular Therapy and Prevention. 2023; 22 (4): 3564 (in Russ.)]. DOI: 10.15829/1728-8800-2023-3564
  9. Roughley M.J., Belcher J., Mallen C.D. et al. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015; 17 (1): 90. DOI: 10.1186/s13075-015-0610-9
  10. Yanai H., Adachi H., Hakoshima M. et al. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int J Mol Sci. 2021; 22 (17): 9221. DOI: 10.3390/ijms22179221
  11. Robinson P.C., Taylor W.J., Dalbeth N. An observational study of gout prevalence and quality of care in a national australian general practice population. J Rheumatol. 2015; 42: 1702–7. DOI: 10.3899/jrheum.150310
  12. Kleinman N.L., Brook R.A., Patel P.A. et al. The impact of gout on work absence and productivity. Value Health. 2007; 10 (4): 231–37. DOI: 10.1111/j.1524-4733.2007.00173.x
  13. Jimenez-Linan L.M., Edwards L., Abhishek A. et al. Online patient information resources on gout provide inadequate information and minimal emphasis on potentially curative urate lowering treatment. Arthritis Care Res (Hoboken). 2017; 69 (5): 748–52. DOI: 10.1002/acr.22981
  14. Jalal D.I. Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review. Curr Med Res Opin. 2016; 32 (11): 1863–9. DOI: 10.1080/03007995.2016.1218840
  15. Neogi T., Jansen T., Daibeth N. et al. 2015 Gout classification criteria: An American College of Rheumatology. European League Against Rheumatism collaborative. Ann Rheum Dis. 2015; 67 (10): 2557–68. DOI: 10.1002/art.39254
  16. Richetty M., Bardin T. Gout. Lancet. 2010; 375 (9711): 318–28. DOI: 10.1016/50140
  17. Doherty M., Jansen T.L., Nuki G. et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012; 71 (11): 1765–70. DOI: 10.1136/annrheumdis-2012-201687
  18. Jennings C.G., Mackenzie I.S., Flynn R. et al. Up-titration of allopurinol in patients with gout. Semin Arthritis Rheum. 2014; 44 (1): 25–30. DOI: 10.1016/j.semarthrit.2014.01.004
  19. Kuo C.F., Grainge M.J., Mallen C. et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015; 74 (4): 661–7. DOI: 10.1136/annrheumdis-2013-204463
  20. Cottrell E., Crabtree V., Edwards J.J. et al. Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice. BMC Fam Pract. 2013; 14: 170. DOI: 10.1186/1471-2296-14-170
  21. McGowan B., Bennett K., Silke C. et al. Adherence and persistence to urate-lowering therapies in the Irish setting. Clin Rheumatol. 2016; 35 (3): 715–21. DOI: 10.1007/s10067-014-2823-8
  22. Juraschek S.P., Kovell L.C., Miller E.R. III et al. Gout, urate lowering therapy and uric acid levels among US adults. Arthritis Care Res. 2015; 67 (4): 588–92. DOI: 10.1002/acr.22469
  23. Ramirez-Sandoval J.C., Madero M. Treatment of hyperuricemia in chronic kidney disease. Contrib Nephrol. 2018; 192: 135–46. DOI: 10.1159/000484288
  24. Беляева И.Б., Мазуров В.И., Трофимов Е.А. Применение биоактивного концентрата мелкой морской рыбы (препарата Алфлутоп): 25 лет в России – исследования и практические выводы. Эффективная фармакотерапия. 2021; 17 (7): 6–12 [Belyaeva I.B., Mazurov V.I., Trofimov E.A. Use of bioactive concentrate of small sea fish (Alflutop): 25 years in Russia – research and practical conclusions. Effective pharmacotherapy. 2021; 17 (7): 6–12 (in Russ.)]. DOI: 10.33978/2307-3586-2021-17-7-6-12
  25. Клинические рекомендации Ассоциации ревматологов России «Подагра». М., 2018 [Clinical recommendations of the Association of Rheumatologists of Russia “Gout”. Moscow: 2018 (in Russ.)]. URL: https://legalacts.ru/doc/klinicheskie-rekomendatsii-podagra-utv-minzdravom-rossii/
  26. Perez-Ruiz F., Herrero-Beites A.M., Carmona L. A two-stage approach to the treatment of hyperuricemia in gout: the «dirty dish» hypothesis. Arthritis Rheum. 2011; 63 (12): 4002–6. DOI: 10.1002/art.30649
  27. Annemans L., Spaepen E., Gaskin M. et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008; 67: 960–6. DOI: 10.1136/ard.2007.076232
  28. Wall G.C., Koenigsfeld C.F., Hegge K.A. et al. Adherence to treatment guidelines in two primary care populations with gout. Rheumatol Int. 2010; 30 (6): 749–53. DOI: 10.1007/ s00296-009-1056-7